Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors
27:28
Precision targeting of MET in NSCLC: A multidisciplinary approach
55:13
Precision targeting of MET in NSCLC: A multidisciplinary approach
31:53
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
17:24
Updates in recurrent/metastatic nasopharyngeal carcinoma: The role of immune checkpoint inhibitors
40:57
Expanding HER2 horizons: Implications for NSCLC and beyond
38:00
Navigating the management of cholestatic pruritus in patients with PBC
1:03:28
MPE webinar: ASH 2024 myeloma and AL amyloidosis highlights
50:02